Literature DB >> 26032132

Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial.

Marie Stentebjerg-Olesen1, Stephen J Ganocy2, Robert L Findling3, Kiki Chang4, Melissa P DelBello5, John M Kane6,7,8,9, Mauricio Tohen10, Pia Jeppesen1, Christoph U Correll11,12,13,14.   

Abstract

In adults with schizophrenia, early response/non-response (ER/ENR) to antipsychotics at 2 weeks robustly predicts ultimate response/non-response (UR/UNR). However, less data about the predictive value of ER/ENR exist in adolescents with schizophrenia. Post hoc analysis of a 6-week trial in adolescents aged 13-17 with schizophrenia were randomized 2:1 to olanzapine or placebo. ER was defined as ≥20 % reduction in Brief Psychiatric Rating Scale-children (BPRS-C) total score at week 2 (ER2) or 3 (ER3); UR was defined with increasing stringency as total BPRS-C score reduction ≥20, ≥30, ≥40 or ≥50 %; remission was defined cross-sectionally using Andreasen et al. (2005) criteria. By week 2 (n = 69) and 3 (n = 66), olanzapine-treated youth achieved 73.3 and 85.5 % of their overall BPRS-C score reduction at 6 weeks last observation carried forward. ER and ENR patients did not differ significantly regarding baseline demographic, illness and treatment variables. ER 2 (frequency = 68.1 %) and ER 3 (frequency = 65.2 %) significantly predicted UR and remission (p = 0.0044-p < 0.0001), with ER3 having more predictive power. A ≥ 20 % BPRS-C reduction threshold for ER had best predictive validity (area under the curve = 0.88-0.92). At 6 weeks, patients with ER had significantly greater improvements in BPRS-C, Clinical Global Impressions Improvement and Severity scores, greater cross-sectional remission and less all-cause discontinuation (p = 0.047-p < 0.0001). Adverse event profiles were similar in the ER and ENR groups. Adolescents with schizophrenia experienced the majority of symptomatic improvement early during olanzapine treatment. ER predicted UR and remission, with ER3 having best predictive power. A ≥ 20 % improvement threshold for defining ER was confirmed as a robust outcome indicator.

Entities:  

Keywords:  Adolescents; Prediction; Remission; Response; Schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 26032132     DOI: 10.1007/s00787-015-0725-1

Source DB:  PubMed          Journal:  Eur Child Adolesc Psychiatry        ISSN: 1018-8827            Impact factor:   4.785


  48 in total

1.  Early prediction of antipsychotic response in schizophrenia.

Authors:  Christoph U Correll; Anil K Malhotra; Saurabh Kaushik; Marjorie McMeniman; John M Kane
Journal:  Am J Psychiatry       Date:  2003-11       Impact factor: 18.112

2.  Remission in first-episode psychosis: predictor variables and symptom improvement patterns.

Authors:  Robin Emsley; Piet P Oosthuizen; Martin Kidd; Liezl Koen; Dana J H Niehaus; H Jadri Turner
Journal:  J Clin Psychiatry       Date:  2006-11       Impact factor: 4.384

3.  Difference in early prediction of antipsychotic non-response between risperidone and olanzapine in the treatment of acute-phase schizophrenia.

Authors:  Kotaro Hatta; Taro Otachi; Yasuhiko Sudo; Tatsuro Hayakawa; Yuko Ashizawa; Hiroshi Takebayashi; Naoki Hayashi; Hiroshi Hamakawa; Shin Ito; Reiko Nakase; Chie Usui; Hiroyuki Nakamura; Toyoaki Hirata; Yutaka Sawa
Journal:  Schizophr Res       Date:  2011-03-21       Impact factor: 4.939

4.  Response trajectories in "real-world" naturalistically treated schizophrenia patients.

Authors:  Rebecca Schennach; Sebastian Meyer; Florian Seemüller; Markus Jäger; Max Schmauss; Gerd Laux; Herbert Pfeiffer; Dieter Naber; Lutz G Schmidt; Wolfgang Gaebel; Joachim Klosterkötter; Isabella Heuser; Wolfgang Maier; Matthias R Lemke; Eckart Rüther; Stefan Klingberg; Markus Gastpar; Richard Musil; Hans-Jürgen Möller; Michael Riedel
Journal:  Schizophr Res       Date:  2012-06-02       Impact factor: 4.939

5.  Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.

Authors:  Ludmila Kryzhanovskaya; S Charles Schulz; Christopher McDougle; Jean Frazier; Ralf Dittmann; Carol Robertson-Plouch; Theresa Bauer; Wen Xu; Wei Wang; Janice Carlson; Mauricio Tohen
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-01       Impact factor: 8.829

6.  First-episode psychosis: a window of opportunity for best practices.

Authors:  Peter F Buckley; Christoph U Correll; Alexander L Miller
Journal:  CNS Spectr       Date:  2007-09       Impact factor: 3.790

7.  Early nonresponse determined by the clinical global impressions scale predicts poorer outcomes in youth with schizophrenia spectrum disorders naturalistically treated with second-generation antipsychotics.

Authors:  Marie Stentebjerg-Olesen; Pia Jeppesen; Anne K Pagsberg; Anders Fink-Jensen; Sandeep Kapoor; Raja Chekuri; Maren Carbon; Aseel Al-Jadiri; Taishiro Kishimoto; John M Kane; Christoph U Correll
Journal:  J Child Adolesc Psychopharmacol       Date:  2013-11-22       Impact factor: 2.576

8.  Identification of early changes in specific symptoms that predict longer-term response to atypical antipsychotics in the treatment of patients with schizophrenia.

Authors:  Stephen J Ruberg; Lei Chen; Virginia Stauffer; Haya Ascher-Svanum; Sara Kollack-Walker; Robert R Conley; John Kane; Bruce J Kinon
Journal:  BMC Psychiatry       Date:  2011-02-09       Impact factor: 3.630

9.  Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs.

Authors:  Hong Liu-Seifert; David H Adams; Bruce J Kinon
Journal:  BMC Med       Date:  2005-12-23       Impact factor: 8.775

10.  Time course for antipsychotic treatment response in first-episode schizophrenia.

Authors:  Robin Emsley; Jonathan Rabinowitz; Rossella Medori
Journal:  Am J Psychiatry       Date:  2006-04       Impact factor: 19.242

View more
  3 in total

Review 1.  Dilemmas in the treatment of early-onset first-episode psychosis.

Authors:  Daniel Hayes; Marinos Kyriakopoulos
Journal:  Ther Adv Psychopharmacol       Date:  2018-03-26

2.  Early Response in Adolescents with Schizophrenia is not Associated with Remission at Six Months.

Authors:  Sadot Arceo; Rosa Elena Ulloa
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2019-08-01

3.  Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics.

Authors:  Yi-Lung Chen; Kun-Po Chen; Chih-Chiang Chiu; Ming-Hong Tai; For-Wey Lung
Journal:  BMC Psychiatry       Date:  2018-12-04       Impact factor: 3.630

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.